Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

UCB Bimz October 2023

With all of the new treatments for psoriasis that have been approved in recent years, is there still an unmet need?

Psoriasis

You, we still have a tremendous unmet need in psoriasis. First of all, we are actually poor at treating psoriatic arthritis. We are still talking about ACR 20, a 20% improvement in arthritis sign and severity scores. So we need to do better than that for arthritis. But even for psoriasis, where we have a lot of drugs and certainly spectacular drugs that have helped our patients a lot, until now, we have not had a single drug that at the end of the placebo controlled period in their pivotal trials, the majority of patients achieve passy 100. Now, finally, with the introduction of bimikizumab in the United States, we have a drug where over 50% center patients achieve passy 100. That means no psoriasis at all. At the end of that placebo control period of 16 weeks, this is the first drug that has ever done that.

With all of the new treatments for psoriasis that have been approved in recent years, is there still an unmet need?

Related CME